SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Madharry who wrote (1173)1/17/2001 11:37:58 PM
From: wolfdog2   of 1386
 
madharry, I think you are focused on the wrong problem with regard to PARS. Management is very experienced. They have gotten two products successfully through the FDA and have a third on the way. I wouldn't worry about their design or ability to pull off a P3 study. The problem with PARS, imo, is that the results of the study are a considerable way off, success is not a sure thing (statistically there is about a 20% failure rate) and interest in the stock is likely to flag until the P3 study nears completion.

On the other hand, the stock seems very cheap given that they do have two products in the market, a third which should be approved in the near future and a deep pipeline in addition to dexanabinal.

So, the risk as I see it is stagnant money. Of course, had you bought when I first mentioned the stock to you, you would have almost doubled your money by now. Perhaps not so stagnant after all. <g>
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News